In a report released today, Joe Gomes from Noble Financial maintained a Buy rating on Medicine Man Technologies (SHWZ – Research Report), with a price target of $4.00. The company’s shares closed last Thursday at $0.82.
Gomes covers the Industrials sector, focusing on stocks such as Orion Group Holdings, DLH Holdings, and CoreCivic. According to TipRanks, Gomes has an average return of 7.4% and a 45.62% success rate on recommended stocks.
Medicine Man Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $3.25, representing a 296.34% upside. In a report released on March 28, Benchmark Co. also maintained a Buy rating on the stock with a $2.50 price target.
Based on Medicine Man Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $42.94 million and a GAAP net loss of $322.46 thousand. In comparison, last year the company earned a revenue of $39.48 million and had a net profit of $1.81 million
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SHWZ in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medicine Man Technologies (SHWZ) Company Description:
Medicine Man Technologies, Inc. engages in the cultivation, marketing, and distribution of medical and recreational cannabis. It provides supply chain, cultivation, dispensary, processing, and feasibility consulting. The company was founded by Andrew Williams on March 20, 2014 and is headquartered in Denver, CO.
